AstraZeneca publishes transcript of ERS 2026 investor call and webcast
AZN•ERS 2026 investor call transcript published
AstraZeneca published a transcript from its “Meet AZN Management: ERS 2026” investor call on Sept. 8, 2026, attended by investors, analysts, and external expert Frank C. Sciurba.
Tozorakimab COPD data and US regulatory timeline
Management highlighted Phase III COPD data for the IL-33 antibody tozorakimab from replicate OBERON and TITANIA studies added to standard inhaled care.
- Primary endpoint met in former smokers: exacerbation rate ratios of 0.71 (p=0.002) in OBERON and 0.66 (p<0.001) in TITANIA.
- Key secondary endpoint met in the overall population: rate ratios of 0.70 in OBERON and 0.71 in TITANIA, each p<0.001.
- Management cited Priority Review in the US with a Q1 2027 PDUFA date, positioning tozorakimab as a potential $5 billion-plus asset.
